Foghorn Discontinues Lilly-Partnered Drug; Pipeline Value Drops for FHTX
Foghorn Therapeutics disclosed it has halted development of a cancer drug co-developed with Eli Lilly after an early-stage trial failed to show sufficient benefit. The setback directly undercuts the value of FHTX’s pipeline and could pressure the stock in the near term, given the Lilly collaboration’s potential milestones and royalties.
View signal analysis